JNJ

At J&J, oncology R&D meets commercial strategy in a quest for new standards of care
Pharma Voice
Thu, 09/19/24 - 09:22 am
JNJ
R&D
oncology
Agency warns J&J over 340B rebate plan
Beckers Hospital Review
Wed, 09/18/24 - 12:26 pm
JNJ
HRSA
340B
drug rebates
ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer
Pharmaphorum
Mon, 09/16/24 - 09:45 am
ESMO
JNJ
Rybrevant
colorectal cancer
J&J leads $50M financing for imaging company Spectrawave
Medtech Dive
Thu, 09/12/24 - 10:20 am
Medtech
Spectrawave
Medical Imaging
venture capital
funding
JNJ
FDA expands J&J's psoriasis drug for inflammatory bowel disease
Reuters
Wed, 09/11/24 - 10:59 pm
JNJ
Tremfya
FDA
ulcerative colitis
J&J Unveils New Branding for Medical Device Units
Medical Devices and Diagnostics Industry
Wed, 09/11/24 - 10:56 pm
JNJ
rebranding
Medtech
Johnson & Johnson MedTech
Ethicon
DePuy Synthes
Biosense Webster
Abiomed
Cerenovous
J&J bolsters Rybrevant-Lazcluze's case against AZ's Tagrisso with survival analysis
Fierce Pharma
Sun, 09/8/24 - 11:38 pm
JNJ
Rybrevant
Lazcluze
AstraZeneca
Tagrisso
non-small cell lung cancer
Evernorth Will Offer a Private-Label Stelara Biosimilar in 2025
Managed Healthcare Executive
Thu, 09/5/24 - 10:32 pm
Evernorth Health
Stelara
biosimilars
Janssen
JNJ
Court tells J&J to pay $1 billion more for 2019 robotics deal
Axios Health
Thu, 09/5/24 - 11:06 am
JNJ
Auris Health
legal
Medtech
robotic surgery
Johnson & Johnson adds $1.1 billion to proposed talc settlement
Reuters
Wed, 09/4/24 - 10:47 pm
JNJ
legal
bankruptcy
J&J submits touted autoimmune disease drug for FDA approval
BioPharma Dive
Thu, 08/29/24 - 11:24 am
JNJ
myasthenia gravis
FDA
nipocalimab
J&J's bid to change pay model for Stelara, Xarelto slammed
Pharmaphorum
Mon, 08/26/24 - 10:16 am
JNJ
Stelara
340B
Xarelto
Targeting AZ's Tagrisso, Johnson & Johnson's Rybrevant combo wins key FDA nod in first-line lung cancer
Fierce Pharma
Tue, 08/20/24 - 11:36 am
JNJ
AstraZeneca
FDA
non-small cell lung cancer
Rybrevant
Lazcluze
Tagrisso
J&J to buy medical device maker V-Wave for up to $1.7 bln
Reuters
Tue, 08/20/24 - 11:08 am
JNJ
M&A
Medtech
V-Wav e
IRA negotiations slash Medicare prices for Big Pharma blockbusters by up to 79%
Fierce Pharma
Thu, 08/15/24 - 11:55 am
Medicare
drug pricing
Inflation Reduction Act
JNJ
Xarelto
Imbruvica
Stelara
Bristol Myers Squibb
Eliquis
Eli Lilly
Jardiance
Merck
Januvia
Amgen
Enbrel
AstraZeneca
Farxiga
Novo Nordisk
Fiasp
Novartis
Entresto
J&J and Roche are the strongest companies in the biopharma industry, says S&P Global
Fierce Pharma
Wed, 08/14/24 - 11:20 am
S&P Global
JNJ
Roche
J&J has enough support for $6.5 bln talc settlement
Yahoo/Reuters
Tue, 08/13/24 - 11:38 am
JNJ
legal
bankruptcy
On doorstep of FDA decision, Gilead pays J&J $320M to exit licensing deal for seladelpar
Fierce Biotech
Fri, 08/9/24 - 11:23 am
Gilead Sciences
seladelpar
liver disease
JNJ
Pharma execs react to final drug price negotiations with Medicare
Pharma Voice
Fri, 08/9/24 - 11:21 am
Medicare
drug pricing
Inflation Reduction Act
Bristol Myers Squibb
Eli Lilly
JNJ
Bayer
Merck
AstraZeneca
Novartis
Amgen
AbbVie
Novo Nordisk
Will Magenta Medical’s Elevate Disrupt the MCS Market?
Medical Devices and Diagnostics Industry
Thu, 08/8/24 - 10:17 pm
Medtech
Magenta Medical
MCS
Elevate
JNJ
Impella

Pages